Key result
GLP-1 receptor agonists may reduce short-term glycemic variability and oxidative stress in early ACS.
Why the study?
Glycemic variability is an independent risk factor associated with increased MACE in ACS, and diabetes treatments differ in their effects on glycemic variability despite similar HbA1c reductions.
Do GLP-1 receptor agonists reduce short-term glycemic variability and oxidative stress in patients with acute coronary syndrome?
Do GLP-1 receptor agonists reduce short-term glycemic variability and oxidative stress in patients with acute coronary syndrome?
This paper hypothesizes that GLP-1 receptor agonists could be beneficial in reducing short-term glycemic variability and oxidative stress during the acute phase of coronary syndromes.
Hypothesis that GLP-1 receptor agonists reduce short-term glycemic variability in ACS is untested; leaves open need for prospective trials.
Glycemic variability (GV) has been recently described as an independent cardiovascular risk factor in patients with acute coronary syndrome (ACS). Also, new findings suggest that GV plays an important role in the development of complications related to impaired glucose metabolism and oxidative stress. On the other hand, although treatment for diabetes can reduce HbA1c in a similar extent their effectiveness over GV can be radically different. Patients in the acute setting of a coronary syndrome should be strictly monitorized to maintain glucose within recommended values; avoiding values lower than 90 mg/dL (5 mmol/L) and higher than 180 mg/dL (10 mmol/L). Also, evidence suggests the importance of not only maintaining glucose within certain values but also decreasing short-term GV as it has been associated with an increase in MACE in these patients. GLP-1 receptor agonists (GLP-1 RA) have demonstrated a decrease in GV and oxidative stress; therefore, the aim of this paper is to hypothesize the beneficial effect of GLP-1 RA in short-term GV and oxidative stress during the initial period of an ACS.
No takes yet. Share an insight, caveat, or question.
Olmo-García et al. (2019) conducted a review in Acute coronary syndrome. GLP-1 receptor agonists was evaluated. The authors hypothesize that GLP-1 receptor agonists may have a beneficial effect on short-term glycemic variability and oxidative stress during the initial period of an acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: